DC Chemicals · Product datasheet

Alfacalcidol — Datasheet

CAT. NO. DCAPI1534

Product page and current package options

ParameterValue
Chemical NameCID 134688803
CAS No.41294-56-8
Synonymsalphacalcidol;VITAMIN D3, 1ALPHA-HYDROXY-;HYDROXYVITAMIN D3;ALFACALCIDOL;1-HYDROXYCHOLECALCIFEROL;1ALPHA-OH-D3;1-alpha-hydroxycholecalciferol;1-ALPHA-HYDROXYVITAMIN D;1(ALPHA)-HYDROXYVITAMIN D3;(1ALPHA,3BETA,5Z,7E)-9,10-SECOCHOLESTA-5,7,10(19)-TRIENE-1,3-DIOL;(1alpha,3beta,5z,7e)-secocholesta-5,7,10(19)-triene-1,3-diol;1,2-HYDROXY CHOLECALCIFEROL;1-hydroxyvitamind3;7,10(19)-triene-1,3-diol,(1-alpha,3-beta,5z,7e)-10-secocholesta-5;alfarol;alpha-hcl;1-α-Hydroxycholecalciferol;1.alpha.-Hydroxyvitamin D3;1a-Hydroxyvitamin D3;1α-Hydroxycholecalciferol;Alpharol;Bondiol;Etalpha;oxydevit;Un Alfa;unalpha;1α-Hydroxyvitamin D3;(1R,3S,E)-5-((Z)-2-((1R,3aS,7aR)-7a-methyl-1-((R)-6-methylheptan-2-yl)dihydro-1H-inden-4(2H,5H,6H,7H,7aH)-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol;CID 134688803
FormulaC27H44O2
M.Wt400.6371
SMILESO([H])[C@@]1([H])C([H])([H])[C@@]([H])(C(=C([H])[H])/C(/C1([H])[H])=C(\[H])/C(/[H])=C1/C([H])([H])C([H])([H])C([H])([H])[C@@]2(C([H])([H])[H])[C@]/1([H])C([H])([H])C([H])([H])[C@]2([H])[C@]([H])(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])O[H]
Purity>99%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

Alfacalcidol (1-hydroxycholecalciferol; Alpha D3; 1.alpha.-Hydroxyvitamin D3) is a non-selective VDR activator medication. IC50 value: Target: VDR activatorAlfacalcidol (1-hydroxycholecalciferol; Alpha D3; 1.alpha.-Hydroxyvitamin D3) improves mechanical bone strength and bone mass; suppresses osteoclastic bone resorption in vivo.

In Vitro

No in vitro data are provided in the current product source. Contact us for further information.

In Vivo

No in vivo data are provided in the current product source. Contact us for further information.

References & source

[1]. Shiraishi et al (2000) Alfacalcidol inhibits bone resorption and stmulates formation in an ovariectomized rat model of osteoporosis: Distinct actions from estrogen. Journal of Bone and Mineral Research. 15 770.

[2]. Ringe JD, Schacht E. et al. Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol. Rheumatol Int. 2004 Jul;24(4):189-97.

[3]. Ivarsen P, Povlsen JV, Christensen KL.Effect of alfacalcidol on cardiac function in patients with chronic kidney disease stage 4 and secondary hyperparathyroidism: A pilot study.Scand J Urol Nephrol. 2012 Jun 25.

[4]. Rianthavorn P,et al. Prevention of bone loss in children receiving long-term glucocorticoids with calcium and alfacalcidol or menatetrenone.J Pediatr Endocrinol Metab. 2012;25(3-4):307-12.

[5]. Ringe JD, Farahmand P, Schacht E.Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients.Rheumatol Int. 2012 Apr 8.

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Cart

Request quotation